In the recent open-label, single-arm, multicenter phase II BEVERLY-2 study, neoadjuvant and adjuvant bevacizumab was added to trastuzumab-based neoadjuvant chemotherapy and adjuvant trastuzumab in patients with nonmetastatic HER2-positive IBC leading to a high pathological complete response (pCR) rate of more than 60% [3] and promising 3-year disease-free survival (DFS) and overall survival (OS) rates of 68 and 90%, respectively. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.